BackAnnovis Bio Overview

Annovis Bio Current Cash

Latest current cash for ANVS: $19B.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$18.73B
↑ 9.33% YoYΔ $1.60B vs prior year quarter

Peer trimmed avg / median

Loading

Annovis Bio Current Cash History

Loading

Annovis Bio vs. peers: Current Cash Comparison

Loading

Annovis Bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Annovis Bio (ANVS) FAQ

As of the most recent data (June 2026), ANVS shows a current cash of $19B. That compares with $17B in the prior-year period — up 9.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ANVS's current cash is now $19B (was $17B) — a 9.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Annovis Bio is outperforming or lagging.

Tracking ANVS's current cash over time shows whether Annovis Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $19B That compares with $17B in the prior-year period — up 9.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Annovis Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $19B) with ownership activity and broader fundamentals.

Annovis Bio's current cash is $19B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.